- Meeting abstract
- Open Access
Excision of the primary in stage IV non-small cell lung cancer (NSCLC): A feasibility study
© Dawson et al. 2015
- Published: 16 December 2015
- Breast Cancer
- Lung Cancer
- Cell Lung Cancer
- Primary Lesion
Benefit from resection of the primary tumour in stage IV renal and breast cancer has been demonstrated. This has never been shown in patients with stage IV lung cancer.
To establish the feasibility of a trial in NSCLC we assessed the proportion of stage IV patients in whom video-assisted thoracoscopic (VAT) wedge resection of the primary lesion would be possible.
A prospective lung cancer database was analysed to identify patients with stage IV lung cancer. Inclusion criteria included: WHO performance status of 0-2 and histologically confirmed NSCLC. Patients with cerebral metastases were excluded. The images of these patients were independently reviewed by two surgeons to determine the suitability for a VATS wedge resection of the primary lesion. Areas of discrepancy were resolved by a third senior reviewer.
Over a 14-month period, 893 patients with stage IV lung cancer were identified. A sample of 300 consecutive patients (34%) with a performance status of 0-2 were analysed of which 30 were excluded as they did not fulfil the primary criteria. Thirty-six (16%) of the remaining 230 had histological confirmation and no cerebral metastases. A further 23 patients were excluded due to the size or location of the primary. Thirteen patients (5.6%): median age 70 years (IQR: 64-76 years) were found to be suitable for a VATS wedge resection and the most common cell type was adenocarcinoma (46%).
A proposed trial of resecting the primary in stage IV NSCLC would be challenging as a busy unit would only have one candidate per month. This data will guide the design of a future multicentre trial.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.